Edition:
India

Aptinyx Inc (APTX.OQ)

APTX.OQ on NASDAQ Stock Exchange Global Select Market

3.81USD
23 Apr 2019
Change (% chg)

-- (--)
Prev Close
$3.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
94,226
52-wk High
$32.25
52-wk Low
$3.45

Latest Key Developments (Source: Significant Developments)

Aptinyx Reports Robust Analgesic Activity Of Its NYX-2925 In Advanced DPN Patients
Thursday, 18 Apr 2019 

April 18 (Reuters) - Aptinyx Inc ::ROBUST ANALGESIC ACTIVITY OF APTINYX’S NYX-2925 IN ADVANCED DPN PATIENTS REVEALED THROUGH FURTHER ANALYSIS OF DATA FROM PHASE 2 STUDY.APTINYX INC - RESULTS SUPPORT AND INFORM FUTURE PHASE 2 STUDY, INITIATION EXPECTED IN 2019.APTINYX INC - MECHANISM OF NYX-2925 IS HIGHLY RELEVANT IN ADVANCED DPN PATIENTS WITH LONGER DURATION OF CHRONIC PAIN.  Full Article

Aptinyx Q4 Loss Per Share $0.42
Thursday, 21 Mar 2019 

March 21 (Reuters) - Aptinyx Inc ::APTINYX REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND HIGHLIGHTS PIPELINE AND BUSINESS PROGRESS.Q4 LOSS PER SHARE $0.42.Q4 EARNINGS PER SHARE ESTIMATE $-0.50 -- REFINITIV IBES DATA.COMPLETED PHASE 2 STUDY OF NYX-2925 IN PAINFUL DPN WHICH DID NOT MEET PRIMARY ENDPOINT.INITIATED FIRST-IN-PATIENT PHASE 2A STUDY OF NYX-783 IN PATIENTS WITH PTSD WITH DATA EXPECTED IN 1H 2020.NEARING COMPLETION OF PHASE 1 STUDY OF NYX-458 IN HEALTHY VOLUNTEERS WITH DATA EXPECTED IN 1H 2019.CASH AND CASH EQUIVALENTS WERE $150.6 MILLION AT DECEMBER 31, 2018 COMPARED TO $92.1 MILLION AT DECEMBER 31, 2017..  Full Article

Aptinyx Inc Initiates Phase 2 Study To Evaluate Safety And Efficacy Of NYX-783 In Patients With Post-Traumatic Stress Disorder
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Aptinyx Inc ::APTINYX INITIATES PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF NYX-783 IN PATIENTS WITH POST-TRAUMATIC STRESS DISORDER.APTINYX INC - PHASE 2 DATA ANTICIPATED 1H 2020.APTINYX INC - DOSED FIRST PATIENT IN A PHASE 2 STUDY OF NYX-783 FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER.APTINYX INC - FAVORABLE SAFETY AND TOLERABILITY, LINEAR PHARMACOKINETICS, AND AMPLE CNS EXPOSURE OF NYX-783 OBSERVED IN PHASE 1.  Full Article

Aptinyx Sees IPO Of 5.3 Mln Shares Priced To Be Between $14 And $16 Per Share – SEC Filing
Monday, 11 Jun 2018 

June 11 (Reuters) - Aptinyx Inc ::APTINYX INC SEES IPO OF 5.3 MILLION SHARES PRICED TO BE BETWEEN $14 AND $16 PER SHARE – SEC FILING.  Full Article

Photo

Allergan depression treatment fails studies, shares slip

Allergan Plc said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker's shares down nearly 4 percent after the bell.